-
2024-513760-26-00
4
2021-09-07
Advanced or Metastatic Urothelial Carcinoma
-
2024-512227-36-00
9
2021-07-28
Advanced solid tumors
-
2024-513870-23-00
5
2021-06-28
Locally Advanced or Metastatic Unresectable Urothelial Cancer
-
2023-506918-45-00
5
2021-05-17
Mild cognitive impairment (MCI) or mild dementia, both of the Alzheime
-
2023-506919-18-00
5
2021-05-17
Mild cognitive impairment (MCI) or mild dementia, both of the Alzheime
-
2024-516681-10-01
4
2021-03-24
central retinal vein occlusions
-
2024-512331-72-00
5
2020-12-22
Squamous Carcinoma of the Anal Canal
-
2023-508443-40-00
5
2020-12-18
Lung Cancer, Non-Small Cell
-
2023-510320-71-00
4
2020-10-27
Squamous cell carcinoma of vulva/vagina
-
2024-515943-44-00
4
2020-10-14
Non small cell lung cancer
-
2024-517141-13-00
3
2020-10-07
Advanced solid tumors, or hematological malignancies and normal hepati
-
2024-516407-16-00
5
2020-04-10
Patients admitted to the ICU proven or suspected infection as the main
-
2024-512537-33-00
5
2019-11-28
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
-
2024-514873-22-00
5
2019-10-16
Unresectable locally advanced and/or metastatic soft-tissue sarcoma
-
2024-516201-23-00
4
2019-08-26
Lung Cancer, NSCLC
-
2022-500785-10-00
5
2019-08-23
Metastatic Castration-Resistant Prostate Cancer
-
2024-511972-33-00
5
2019-08-05
Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-
-
2024-513977-31-00
4
2019-07-17
Untreated squamous cell carcinoma of the head and neck
-
2022-500797-34-00
4
2018-12-17
Treatment of participants with positive cancer for HRRm or HRD.
-
2024-512158-12-00
5
2018-12-14
Bladder Cancer
Muscle-Invasive Bladder Cancer
-
2024-514179-17-00
5
2018-10-02
Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cerv
-
2022-500251-22-00
4
2018-04-12
This study will include all patients having received at least one infu
-
2024-516904-40-00
5
2018-03-27
Previously Untreated Diffuse large B-cell lymphoma (DLBCL)
-
2024-517439-39-00
7
2018-03-19
Metastatic castration-resistant prostate cancer.